# Arrowhead Pharmaceuticals (ARWR) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ARWR/thesis · /stocks/ARWR/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ARWR
step: 04
title: Financial Quality & Adversarial Research Sweep
date: 2026-06-09
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Arrowhead Pharmaceuticals (ARWR)

#### 1. Statement-Quality Assessment

##### Income Statement Quality

**Revenue recognition under ASC 606:**
The single most important quality issue for ARWR's income statement is the episodic, large-lump recognition of collaboration and license revenue. Arrowhead accounts for performance obligations in collaboration agreements and recognizes upfronts over the performance period. [S1]

Key quality issues to note:
- **FY2025 Q2 ($542.7M in one quarter):** The Sarepta deal ($825M+ upfront) creates a one-time revenue spike that is NOT a proxy for run-rate cash generation. Reported FY2025 revenue of $829.4M and operating income of $98.4M are not indicative of sustainable profitability.
- **Deferred revenue dynamics:** Large upfronts create deferred revenue on the balance sheet; as obligations are satisfied, deferred revenue converts to income. This creates a potential GAAP income stream that doesn't correspond to cash received in the same period. At FY2024, deferred revenue from collaborations was ~$103.2M current + $845.6M noncurrent. [S1]
- **R&D expense: all internal R&D is expensed** — no capitalization of drug development costs under US GAAP (they treat FDA approval as the first point where technological feasibility is established). This understates asset value but is standard practice.

**Operating expense quality:**
- R&D expense is the most reliable metric: $607M FY2025, growing ~20% YoY. Breakdowns suggest genuine platform expansion, not padding.
- G&A jumped to $123.9M FY2025 vs. $98.8M FY2024 (+25%) — reflects commercial infrastructure build-up post-plozasiran NDA. G&A as % of R&D is ~20%, reasonable for a company transitioning to commercial stage.
- SBC: declining from $120.9M (FY2022 peak) to $63.4M (FY2025) — positive signal of cost discipline; SBC as % of total revenue was 7.6% in FY2025 vs. inflated in prior years.

**Adjustments recommended:**
1. **Normalize revenue** to deal-adjusted basis: strip out one-time upfronts, focus on milestone cadence and product revenue run-rate
2. **Cash-basis P&L:** Operating cash flow is more informative than GAAP net income for ARWR; FY2025 OCF of $179.6M (positive) vs. FY2024 ($462.9M) (deeply negative)
3. **Exclude non-cash SBC** from EBITDA-like metrics — though SBC is real dilution, it inflates reported OpEx vs. cash burn

##### Balance Sheet Quality

**Total debt build:**
- FY2021: $25.5M (near debt-free)
- FY2022: $81.6M (convertible notes)
- FY2023: $383.5M (Royalty Pharma royalty liability + convertibles)
- FY2024: $851.9M ($400M Sixth Street term loan + Royalty Pharma + convertibles)
- FY2025: $733.7M (some repayment/reclassification)
- Q2 FY2026: $1,373M (major new financing — likely new convertible notes)

**Royalty liability complexity:**
In November 2022, Arrowhead sold its royalty rights on olpasiran (Amgen's Lp(a) drug) to Royalty Pharma for $250M upfront, structured as a **non-recourse royalty purchase** that is classified as debt on Arrowhead's balance sheet under US GAAP. This is a real liability if olpasiran royalties are sufficient to repay it, but it is effectively contingent on Amgen's clinical success. [S1]

**Sixth Street term loan ($400M drawn, Sep 2024):**
- 7-year term, secured by all ARWR assets
- Interest rate ~9–10% (estimated based on prevailing lending terms for clinical-stage biotechs)
- Annual interest expense: ~$36–40M (material cash cost)
- Covenant risk: If clinical programs fail and the company cannot service the debt, this could be a significant distress risk

**Equity quality:**
- Stockholders' equity: $466.1M (FY2025); recovered from near-wipe-out level of $56M in Q1 FY2025
- Book value is largely intangible in practice — most of ARWR's value is in its pipeline IP, not on the balance sheet
- Accumulated deficit at FY2025: Very large (>$2B accumulated losses since inception) — standard for clinical-stage biotech

**Cash quality:**
- FY2025: $88.7M cash + $692.4M short-term investments = $781M liquid
- Q2 FY2026: $147.5M cash (ST investments not separately broken out at Q2 FY2026) — may have been deployed or reclassified
- Q2 FY2026 total assets jumped to $2,268M (from $1,385M at FY2025) — new debt raises likely went to the balance sheet as cash/investments

##### Cash Flow Statement Quality

- **Operating cash flow is the most reliable signal** — it removes deferred revenue and non-cash items
- Q2 FY2026 OCF: $84.4M (positive, suggests Q2 had net cash inflows); Q1 FY2026: $13.5M (positive)
- FY2025 cumulative quarterly OCF: $460M (Q2 FY2025 large receipt) + ($154.7M) + ($146.3M) + $20.5M = $179.5M for the year
- CapEx has normalized to ~$2–8M/quarter in FY2026 after the facility build ($141–177M/year in FY2023–FY2024)

---

#### 2. Adversarial Research Sweep

*Note: No earnings transcripts available on this research path. Adversarial concerns are sourced from SEC filings (10-K risk factors), press coverage, proxy analysis, and insider transaction data.*

##### Issue 1: Say-On-Pay Failure at 2026 Annual Meeting

**What happened:** At the March 19, 2026 Annual Meeting, say-on-pay vote FAILED with 59% of votes cast AGAINST management compensation. 41.6M shares voted FOR, 59.9M shares voted AGAINST — a significant shareholder rebellion. [S3]

**Why it matters:**
- CEO Christopher Anzalone received $9.0M total compensation in FY2025, with $6.8M in RSU grants
- The compensation committee's lead (Michael Perry) received only 69% shareholder support — the lowest of any director
- A new equity plan authorizing 10.5M additional shares was approved (overhang increasing from 5.6% to 11.8% of shares outstanding)
- Say-on-pay failures are rare and signal deep investor dissatisfaction with governance

**Analysis:** The combination of (a) CEO dual role as Chairman + CEO (no independent chair), (b) large equity grants in a year with near-zero product revenue (FY2024 was a trough year), and (c) the 10.5M share equity plan authorization — totaling ~7.5% dilution — appears to have crystalized shareholder frustration.

**Governance red flag severity: MEDIUM-HIGH.** This does not impair the scientific thesis but it signals a management-shareholder alignment problem that could lead to further governance changes, compensation restructuring, or activist involvement.

##### Issue 2: CEO and Insider Selling

**What happened:** CEO Anzalone sold approximately 347,055 shares in December 2025 (~$23.1M at $64–69/share). Multiple directors also sold in the same December 2025 window. Estimated total insider sales over 12 months (Sep 2025–May 2026): $37–40M. [S3]

**Analysis:** December 2025 window (6 weeks post-FDA approval in November 2025) was the first open trading window after the approval catalyst. Selling post-approval is standard for executives who have been holding through the development period and is covered under 10b5-1 plans. However:
- The timing (peak price window) and scale ($23M single executive) is aggressive
- New CFO Daniel Apel (joined May 2025) also sold $934K (April 2026) and filed Form 144 for an additional 100,000 shares
- CEO's sale of 347K shares represents ~0.25% of shares outstanding — not a catastrophic signal but notable

**Red flag severity: MEDIUM.** No insider buying visible. Selling clusters are a caution signal but not a definitive thesis killer.

##### Issue 3: Debt Load and Runway

**What happened:** Total debt rose from near-zero ($25.5M in FY2021) to $1,373M by Q2 FY2026. [S2]

**Components:**
- Royalty Pharma liability (~$250M, related to olpasiran royalty sale — non-recourse per Amgen clinical success)
- Sixth Street term loan ($400M, drawn Sep 2024; 7-year, secured)
- Convertible notes (likely new tranche in Q2 FY2026 given asset jump from $1.4B to $2.3B)

**Cash analysis:**
If Q2 FY2026 total assets jumped $883M ($1,385M → $2,268M) and total debt jumped $639M ($733M → $1,373M), the new debt is likely mostly on the balance sheet as liquid assets (~$640M net inflow). This suggests ARWR raised a large convertible note tranche in Q1 or Q2 FY2026, adding meaningful runway.

Revised liquid assets estimate (Q2 FY2026): ~$147.5M reported cash + ~$640M estimated ST investments from new raise = ~$787M liquid

At ~$215–223M/quarter burn, current liquidity covers approximately 3.5 years without any additional revenue — comfortable for a company with multiple Phase 3 programs expected to read out in 2026–2027.

**Red flag severity: LOW-MEDIUM.** Debt is elevated but appears manageable given large liquid assets and ongoing deal flow. Risk escalates if Phase 3 programs fail and no new deals materialize.

##### Issue 4: R&D Burn Acceleration

**What happened:** Quarterly R&D jumped from $133–137M in early FY2025 to $177M in Q1 FY2026 (+30% YoY). G&A jumped from $26.9M to $46.0M (+71% YoY) in Q1 FY2026 vs. Q1 FY2025. [S2]

**Analysis:** The G&A spike is directly attributable to REDEMPLO commercial infrastructure (commercial team, sales force, patient access programs). R&D acceleration reflects pipeline advancement with 6 Phase 3 programs running simultaneously. Both are "good" spending increases in the context of pipeline/commercial advancement, but they increase the burn rate significantly.

**Red flag severity: LOW.** Accelerating spend is expected; concern would arise only if burn rate exceeds runway.

##### Issue 5: No Product Revenue Track Record

**What happened:** Arrowhead generated no product revenue through FY2024. REDEMPLO launched November 2025.

**Analysis:** The company has never built or operated a commercial infrastructure. FCS is an ultra-rare disease requiring unusual diagnostic steps (patients often go years without a diagnosis). The commercial team is being assembled from scratch. 400+ prescriptions in the first commercial quarter is an early positive signal, but it's too early to conclude commercial execution is proven.

**Red flag severity: MEDIUM.** Commercial execution risk is real but manageable; FCS is a "practice" market for the larger sHTG opportunity.

---

#### 3. Financial Quality Score

| Dimension | Score | Notes |
|-----------|-------|-------|
| Revenue quality | 3/10 | Highly episodic; deal-dependent; not comparable YoY |
| Earnings quality | 3/10 | GAAP earnings completely dominated by deal timing |
| Cash flow quality | 7/10 | OCF is more reliable; normalize for deal receipt timing |
| Balance sheet quality | 5/10 | Assets clean; liabilities complex (Royalty Pharma, term loan, converts) |
| Governance quality | 4/10 | CEO/Chair dual role; say-on-pay failure; aggressive insider selling |
| Disclosure quality | 8/10 | 10-K disclosures are comprehensive; pipeline updates are detailed |

---

#### 4. Source Index

[S1] XBRL Financial Summary + 10-K FY2024 — ARWR_financials/xbrl/ + sec_filings/
[S2] StockAnalysis Financial Summary — ARWR_financials/other/stockanalysis_summary.md
[S3] Governance + Insider Transactions — ARWR_financials/proxy/
[S4] Consensus & News — ARWR_financials/other/consensus.md

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ARWR/fundamental

## Navigation

- Overview: /stocks/ARWR
- Financials (this page): /stocks/ARWR/financials
- Thesis: /stocks/ARWR/thesis
- Investment Memo: /stocks/ARWR/memo
- Coverage universe: /stocks